News from Tuesday, March 3, 2026
Articles
Cochrane Evidence to Inform OpenEvidence Users
(3/3, Cochrane) comments “...The partnership includes Cochrane Clinical Answers, a curated collection of actionable clinical insights drawn from Cochrane reviews. Developed by experts and grounded in Cochrane’s world-leading methodological standards, Cochrane Clinical Answers translate complex research into practical insights. Each answer distils high-quality evidence into an accessible format that supports rapid clinical decision-making at the point of care, and will now help to inform OpenEvidence users.” Full
Drugmakers Pressure Trump to Withdraw Foreign Pricing Frameworks
(3/3, Nyah Phengsitthy, Bloomberg Law) ...‘Imposing pricing policies that introduce additional unpredictability-particularly those tied to foreign price benchmarks-could dampen investment in areas where investments are especially high risk but may yield revolutionary new therapies,’ the Biotechnology Innovation Organization...said to [CMS]. The Pharmaceutical Research and Manufacturers of America, the drug industry's influentiallobbying arm, similarly urged the government to withdraw its plans."... Subscription Required
In 1 State, Large Hospitals Dominate 340B's Net Savings
(3/2, Dave Muoio, Fierce Healthcare) reports “...When looking at the types of organizations that participated, the [Minnesota Department of Health] found 23 large hospitals that qualified for the program due to their disproportionate share hospital designation generated ‘by far the largest net revenues.’ Those comprised 12% of the state's 181 reporting entities but together tallied more than 80% ($1.08 billion) of Minnesota covered entities' collective net 340B revenue. That amount averaged out to just over $47 million per hospital, with a few entities driving a particularly outsized portion of the activity: M Health Fairview - University of Minnesota Medical Center ($334.7 million net 340B revenue, or 26.1% of the state's total), Abbott Northwestern Hospital ($154 million, or 12%) and Hennepin Healthcare ($99.7 million, 7.8%).” Full
Press Releases
ICER Publishes Special Report on Treatment for Ulcerative Colitis and Crohn’s Disease as Part of CMS Public Comment Process on Medicare Drug Price Negotiations
(3/3, ICER Press Release) “The Institute for Clinical and Economic Review (ICER) today posted a Special Report on Entyvio® (vedolizumab, Takeda Pharmaceutical Co. Ltd.) for the treatment of ulcerative colitis and Crohn’s disease. This report will be submitted to the Centers for Medicare & Medicaid Services (CMS) as part of the 2026 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2028.” Full
Loopback Health Expands Partnership with Cornerstone AI to Accelerate Real-World Evidence with +99% Data Accuracy
(3/3, Cornerstone AI Press Release) “...‘Pharma executives and data teams are often slowed by manual data preparation that delays scientific insights,’ said Viraj Narayanan, CEO of Cornerstone AI. ‘By applying our AI data patterns to automatically standardize procedure data, we are eliminating the grunt work that creates bottlenecks. Our proprietary pattern library allows us to solve data quality issues instantly, ensuring Loopback's life sciences partners get analysis-ready data with the speed and precision required to drive commercial and clinical strategy.’” Full
Milliman MedInsight Integrates AI and Next-Generation Analytics to Strengthen Value-Based Care Decision-Making
(3/3, Milliman MedInsight Press Release) “...As value-based arrangements continue to grow in sophistication, Milliman MedInsight is expanding its VBC Contracts application to better support contract design and evaluation. Planned 2026 enhancements include new scenario modeling capabilities, broader contract templates, and a contract builder that helps organizations compare potential arrangements and understand financial implications with greater clarity.” Full
Journals
Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. On-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials
Rehan Ishaque, et al.
January - December 2026, Clinical and Applied Thrombosis/Hemostasis
Risk of Acute Myocardial Infarction with Ticagrelor, Prasugrel, and Clopidogrel Prescription after Coronary Stent Restenosis: A Retrospective Real-World Comparative Risk Analysis with TriNetX
Yesh V Dhruva, et al.
March 1, 2026, Heart & Lung
Comparative Effectiveness of Volumetric Modulated Arc Therapy Versus Tomotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score-Matched Retrospective Cohort Study
Zihan Chen, et al.
March 2, 2026, Radiation Oncology
Endoscopic Resection Versus Surgery for T1 Rectal Cancer: A Systematic Review and Meta-Analysis of Oncologic and Safety Outcomes
Yeajin Moon, et al.
March 2, 2026, Surgical Endoscopy
Comparative Effectiveness of Misoprostol plus Letrozole Versus Misoprostol Alone for Pharmacological Abortion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Katherine Ann Reimão Miller, et al.
March 3, 2026, The European Journal of Contraception & Reproductive Health Care
Bariatric Surgery Versus Pelvic Floor Muscle Training: Which is Superior for Managing Urinary Incontinence?
Hui Peng, et al.
March 3, 2026, Obesity Surgery
Reports
Special Assessment to Inform CMS Drug Price Negotiations: Vedolizumab (Entyvio®) for Ulcerative Colitis and Crohn’s Disease
March 3, 2026